• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Sugar acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Sugar acids and derivatives

Recent Advances in the Study of Ciclopirox β-D-Glucuronide (CAS: 79419-54-8): A Comprehensive Research Brief

Ciclopirox β-D-Glucuronide (CAS: 79419-54-8) is a glucuronide conjugate of the antifungal agent ciclopirox, which has garnered significant attention in recent years due to its potential therapeutic applications and unique pharmacokinetic properties. This research brief aims to provide an up-to-date overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and clinical relevance. The information presented herein is derived from peer-reviewed publications, conference proceedings, and industry reports published within the last three years.

The synthesis of Ciclopirox β-D-Glucuronide involves the enzymatic conjugation of ciclopirox with glucuronic acid, a process primarily mediated by UDP-glucuronosyltransferases (UGTs). Recent studies have highlighted the role of specific UGT isoforms, such as UGT1A9 and UGT2B7, in the metabolism of ciclopirox, shedding light on interindividual variability in drug metabolism. Advanced analytical techniques, including LC-MS/MS and NMR spectroscopy, have been employed to characterize the structure and purity of the compound, ensuring its suitability for further pharmacological evaluation.

Pharmacologically, Ciclopirox β-D-Glucuronide has demonstrated intriguing properties beyond its role as a metabolite. While traditionally considered an inactive byproduct, emerging evidence suggests that this conjugate may retain some antifungal activity, albeit at a reduced potency compared to the parent compound. Recent in vitro studies have explored its efficacy against dermatophytes and Candida species, with particular interest in its potential to overcome resistance mechanisms observed with ciclopirox alone. Additionally, its improved water solubility and altered tissue distribution profile make it an attractive candidate for formulation development.

From a clinical perspective, research has focused on understanding the pharmacokinetic behavior of Ciclopirox β-D-Glucuronide in human subjects. Population pharmacokinetic modeling has revealed significant correlations between genetic polymorphisms in UGT genes and the plasma concentrations of this metabolite. These findings have important implications for personalized medicine approaches in antifungal therapy. Furthermore, the compound's excretion profile and potential for drug-drug interactions have been systematically investigated, providing valuable data for clinical decision-making.

Recent technological advancements have enabled more detailed studies of Ciclopirox β-D-Glucuronide's molecular interactions. Molecular docking simulations and surface plasmon resonance (SPR) experiments have provided insights into its binding affinity for various biological targets. These studies have uncovered unexpected interactions with inflammatory mediators, suggesting potential immunomodulatory effects that warrant further investigation. Such findings may expand the therapeutic applications of ciclopirox-derived compounds beyond their traditional antifungal indications.

In conclusion, Ciclopirox β-D-Glucuronide represents a fascinating subject of contemporary research in medicinal chemistry and pharmacology. While much progress has been made in understanding its properties and potential applications, several questions remain unanswered. Future research directions may include exploring its role in combination therapies, investigating its tissue-specific effects, and developing novel formulations that leverage its unique physicochemical characteristics. The continued study of this compound promises to yield valuable insights that could influence the development of next-generation antifungal agents.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)